Bora Pharmaceuticals, a global leader in pharmaceutical manufacturing, will attend this year’s Convention on Pharmaceutical Ingredients (CPHI) event in Frankfurt from October 28-30.
Bora has a strong presence planned for CPHI 2025: Chair and CEO, Bobby Sheng, was announced as a finalist for "CEO of the Year" and CDMO president, J.D. Mowery, will join other industry leaders in a panel discussion on the future of CDMO innovation.
Building on its leadership in pharmaceutical manufacturing, Bora Pharmaceuticals is expanding its biologics capabilities through a strategic fill-and-finish partnership with Bora Biologics, enhancing its ability to deliver fully integrated, end-to-end CDMO solutions. Both are attending CPHI.
For more than 30 years, CPHI has brought together the brightest minds and most influential companies shaping the global pharmaceutical industry to collaborate and learn.
CPHI Pharma Awards celebrate the forefront of innovation and excellence in the pharmaceutical industry.
Bora CEO, Bobby Sheng, is a 2025 finalist and the 2020 winner of the "CEO of the Year" award, which recognises outstanding leadership within the pharma industry, excelling in areas such as product success, global reach, leadership vision, corporate strategy and more.
Throughout the convention, CPHI will be hosting a variety of educational programs, including the panel Beyond Traditional Markets: The Strategic Importance of Emerging Pharma Trends and CDMO Innovation, which will feature J.D. Mowery, president of Bora’s CDMO business, as a panellist.
The session will explore the emerging trends shaping CDMOs, with insights from industry leaders who have firsthand experience navigating these challenges and opportunities.
The panel is scheduled for October 30 from 11:35 am to 12:15 pm.
Bora experts will be available in the CDMO Zone at Booth 6.0C90, where attendees can schedule one-on-one meetings to learn more about Bora Pharmaceutical’s expertise and capacity, as well as Bora Biologics’ capabilities.
“Bringing leaders and ideas together under one roof to collaborate is critical to the future growth of our industry,” said Mowery.
“This has been an exciting year at Bora, marked by global growth and strategic investments across our business. We’re eager to make the most of the connections and collaboration at CPHI and carry those insights back to our customers to further strengthen the value we deliver.”
Marc Goemans, Chief Commercial Officer of Bora Biologics, emphasised: “Our collaboration with Bora Pharmaceuticals for sterile fill and finish services truly distinguishes us from other biologic CDMOs."
"It streamlines the client experience by allowing them to sign a single agreement to work with one team on one timeline, ensuring expedited project success from start to finish — consolidating expertise and rewarding collaboration to derisk every project."